“compound 38a” is an inhibitor of ChemR23, a chemokine-receptor-like GPCR with a role in plasmacytoid dendritic cell (pDC) trafficking. The ChemR23 inhibitor was developed with the intention of suppressing the migration of pDCs, which may be useful in certain autoimmune diseases. A key change that dramatically improved bioavailability was [...]
< 1 minute read
Sep. 18, 2021
Compound 38a: An Orally Active ChemR23 GPCR Inhibitor
"compound 38a"
orally active ChemR23 GPCR inhibitor oral effects on dendritic cells in higher species from cell-based screen and optimization Bioorg. Med. Chem., Jul. 14, 2020 Kyowa Kirin, Shizuoka, JP
Loading...
